Genentech, Inc.

Rutgers, the State University of New Jersey

Curis, Inc.

Genetech, Inc.

Robert A Lazarus

Mark S Dennis

Yingnan Zhang

Stephen P Anderson

Weiru Wang

Yan Wu

Daniel Kirchhofer

David B Powers

Mark Hurle

Jana Seymour Ulmer

Ryan Jefferson Watts

Jasvinder Atwal

Cecilia Pui Chi Chiu

Yongmei Chen

Henry R Maun

Wei Ey Li

Robert F Kelley

Christian Wiesmann

Daniel J Burdick

Maureen H Beresini

Nicholas Skelton

Mark Ultsch

Geoffrey F Lee

Charles Eigenbrot, Jr

Clark Qun Pan

John Quinn

David Aaron Estell

Wei-Ching Liang

Frederic J De Sauvage

Jo-Anne Hongo

David Richard Light

William H Rastetter

Meredith C Hazen

Steven Elliot Kauder

Steven Shak

Suzanna J Scales

Harvey I Miller

Sarah G Hymowitz

Kyle Landgraf

Jackson G Egen

Charles Eigenbrot

R Kevin Stafford

Jana L Seymour

Jeffrey V Miller

Lydia Santell

Ivan Bosanac

Xiaohui Wen

Daniel K Kirchhofer

Jose F Bazan

The invention provides PCSK9 inhibitors, compositions comprising the PCSK9 inhibitors, and methods of identifying and using the PCSK9 inhibitors.

Compositions and methods for treating cardiovascular disease

Provided are novel, non-naturally occurring chagasin scaffold proteins derived from chagasin or chagasin-like protease inhibitor proteins. Also provided are libraries of non-naturally occurring chagasin scaffold proteins and methods of using such libraries to generate non-naturally occurring chagasin scaffold proteins that specifically bind to a target ligand. The present invention further provides methods of using non-naturally occurring chagasin protein scaffold that bind to a target ligand, including diagnostic and therapeutic compositions and methods. The invention also provides novel non-naturally occurring chagasin scaffold proteins that specifically bind low density lipoprotein receptor-related protein 6 (LRP6) and novel non-naturally occurring chagasin scaffold proteins that specifically bind vascular endothelial growth factor (VEGF).

Chagasin-based scaffold compositions, methods, and uses

This invention relates to RON compositions, in particular RON composition comprising a RON agonist, and methods of using the compositions for the treatment of diseases. The invention also relates to diagnosis of RON-associated or MSP-associated diseases.

Method of reducing blood glucose by administering RON agonists

The invention provides antibodies to specific neural proteins and methods of using the same.

Nucleic acid molecules encoding for BACE1 antibodies

The invention provides peptide inhibitors of BACE1 that bind to the active site in a noncanonical fashion, and methods of use thereof.

Peptide inhibitors of BACE1

Methods and compositions for neural disease immunotherapy

BACE1 antibodies

The present invention is directed to derivatives of Hhip1 and methods of using the same for treatment and diagnosis of cancer in mammals.

Variant Hhip1 protein and methods and uses thereof

Provided herein are zymogen activating molecules such as zymogen activating peptides, and methods of identifying and using these zymogen activating molecules such as zymogen activating peptides.

Zymogen activators

The invention provides HGF/Met modulators comprising HGF having mutations in regions that affect HGF function, and antagonists that target said regions. The invention further provides methods of identifying, making and using these modulators.

HGF &#x3b2; chain variants

HGF beta chain variants

The present invention relates to amino acid sequence variants of human DNase I that have increased DNA-hydrolytic activity. The invention provides nucleic acid sequences encoding such hyperactive variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of hyperactive-variants of human DNase I.

Human DNase I hyperactive variants

Mutants of 2,5-diketo-D-gluconic acid reductase A, an enzyme used to produce 2-keto-L-gulonic acid, a precursor of ascorbic acid (vitamin C) are prepared by site-directed mutagenesis. These mutants have increased catalytic activity, increased expression levels, and/or enhanced temperature stability.

Enzymes for the production of 2-keto-L-gulonic acid

Growing community of inventors

Millbrae, CA, United States of America

Robert A Lazarus